Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › ramosetron

ramosetron

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of ramosetron

3 trials tracked of ramosetron: 1 in phase 3 or 4.

3Trials tracked
1Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 4 1 Other / NA 2
  1. Phase 4 Additional Anti-emetic Effect of Ramosetron Prophylaxis After Total Knee Arthroplasty Completed
  2. N/A Postoperative Nausea and Vomiting: Ramosetron Plus Aprepitant vs Palonosetron Plus Aprepitant Completed
  3. N/A Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis Completed

Showing the 3 most-cited and recently-updated of 3 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Network meta-analysis compares 5-HT3 antagonists with or without dexamethasone for highly emetogenic chemotherapy-induced nausea and vomiting
Oncology Meta-analysis
Network meta-analysis compares 5-HT3 antagonists with or without dexamethasone for highly emetogenic chemotherapy-induced nausea and vomiting New analysis suggests palonosetron plus dexamethasone may reduce delayed vomiting in chemotherapy patients
This network meta-analysis evaluated 5-hydroxytryptamine-3 (5-HT3) receptor antagonists with or without dexamethasone in patients undergoing…
Combining palonosetron with dexamethasone reduces delayed vomiting in chemotherapy patients better than other common drug options.
Apr 9, 2026